News

This clinical trial is designed to assess the safety of TG-C in patients who have opted for total knee arthroplasty. TissueGene has developed TG-C to regenerate cartilage in

Tysabri was removed form the market following its original 2004 approval after it was shown to increase the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection

Symbicort, which is already approved in Europe, is a twice-daily asthma therapy combining budesonide, an inhaled corticosteroid, and formoterol, a rapid and long-acting beta2-agonist into one inhaler. AstraZeneca

Paliperidone, a new chemical entity, is the first and only atypical antipsychotic to use the OROS extended release technology. This technology provides a continuous release of medication over

If approved the product will be the first and only ADHD stimulant product that controls inattention, hyperactivity and impulsivity for up to 16 hours. The application is subject

Arxxant (ruboxistaurin mesylate) is an investigational oral drug for the treatment of moderate to severe non-proliferative diabetic retinopathy, a diabetic eye disease. The co-promotion agreement is subject to

Advanced Influenza Technologies (AIT) holds the license for a DNA-based Influenza vaccine candidate developed at the University of Massachusetts Medical School. “Years of effort have been expended developing

The contract will run for a period of two years with an initial contract award amount of $16.8 million. Under the contract, 59 jurisdictions will be able to

Hereditary angioedema (HAE) is a human genetic disorder caused by a shortage of C1 inhibitor activity. The disease is characterized by acute attacks of painful swelling of soft